JPS6147838B2 - - Google Patents
Info
- Publication number
- JPS6147838B2 JPS6147838B2 JP54500118A JP50011878A JPS6147838B2 JP S6147838 B2 JPS6147838 B2 JP S6147838B2 JP 54500118 A JP54500118 A JP 54500118A JP 50011878 A JP50011878 A JP 50011878A JP S6147838 B2 JPS6147838 B2 JP S6147838B2
- Authority
- JP
- Japan
- Prior art keywords
- product
- ethyl
- melting point
- quinolizidine
- indolo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 76
- 239000000047 product Substances 0.000 description 39
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 35
- 150000001875 compounds Chemical class 0.000 description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 29
- 238000002844 melting Methods 0.000 description 29
- 230000008018 melting Effects 0.000 description 29
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 28
- -1 ethoxycarbonylaminomethyl Chemical group 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 27
- 239000000203 mixture Substances 0.000 description 25
- 238000004519 manufacturing process Methods 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 14
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 13
- 238000001704 evaporation Methods 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 150000001408 amides Chemical class 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 230000008020 evaporation Effects 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- RXPRRQLKFXBCSJ-UHFFFAOYSA-N dl-Vincamin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-UHFFFAOYSA-N 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 229960002726 vincamine Drugs 0.000 description 7
- OURDZMSSMGUMKR-UHFFFAOYSA-N 1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizine Chemical compound C1=CC=C2C(CCN3CCCCC33)=C3NC2=C1 OURDZMSSMGUMKR-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
- 235000011121 sodium hydroxide Nutrition 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 5
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- LJPZHJUSICYOIX-UHFFFAOYSA-N quinolizidine Chemical group C1CCCC2CCCCN21 LJPZHJUSICYOIX-UHFFFAOYSA-N 0.000 description 4
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 4
- FQMWCEMJFGFVRN-UHFFFAOYSA-N 2,3,4,6,7,8,9,9a-octahydro-1h-quinolizine;perchloric acid Chemical compound [O-]Cl(=O)(=O)=O.C1CCCC2CCCC[NH+]21 FQMWCEMJFGFVRN-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 230000001588 bifunctional effect Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- 238000004452 microanalysis Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 3
- 238000004454 trace mineral analysis Methods 0.000 description 3
- DIOKNYUWXBKNEH-UHFFFAOYSA-N (1-ethyl-3,4,6,7,12,12b-hexahydro-2H-indolo[2,3-a]quinolizin-1-yl)methanamine Chemical compound C(C)C1(CCCN2CCC3=C(C12)NC1=CC=CC=C13)CN DIOKNYUWXBKNEH-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000012024 dehydrating agents Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- KUFHJQFMMNBZFK-UHFFFAOYSA-N ethyl 1-ethyl-3,4,6,7,12,12b-hexahydro-2H-indolo[2,3-a]quinolizine-1-carboxylate Chemical compound C(C)C1(CCCN2CCC3=C(C12)NC1=CC=CC=C13)C(=O)OCC KUFHJQFMMNBZFK-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- MHCFAGZWMAWTNR-UHFFFAOYSA-M lithium perchlorate Chemical compound [Li+].[O-]Cl(=O)(=O)=O MHCFAGZWMAWTNR-UHFFFAOYSA-M 0.000 description 2
- 229910001486 lithium perchlorate Inorganic materials 0.000 description 2
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- NBOOZXVYXHATOW-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-ylmethyl)piperazine Chemical compound C=1C=C2OCOC2=CC=1CN1CCNCC1 NBOOZXVYXHATOW-UHFFFAOYSA-N 0.000 description 1
- UQPHNFNHAQUPFG-UHFFFAOYSA-N 1-ethyl-3,4,6,7,12,12b-hexahydro-2H-indolo[2,3-a]quinolizine-1-carboxylic acid Chemical compound C(C)C1(CCCN2CCC3=C(C12)NC1=CC=CC=C13)C(=O)O UQPHNFNHAQUPFG-UHFFFAOYSA-N 0.000 description 1
- MOTOAJXWIMNNGV-UHFFFAOYSA-N 2-(1h-indol-3-yl)ethanamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1.C1=CC=C2C(CCN)=CNC2=C1 MOTOAJXWIMNNGV-UHFFFAOYSA-N 0.000 description 1
- BUHYMJLFRZAFBF-UHFFFAOYSA-N 3,4,5-trimethoxybenzoyl chloride Chemical compound COC1=CC(C(Cl)=O)=CC(OC)=C1OC BUHYMJLFRZAFBF-UHFFFAOYSA-N 0.000 description 1
- SKPGDHHYCYKJIK-UHFFFAOYSA-N 5-chloro-2-cyano-2-ethylpentanoyl chloride Chemical compound CCC(C(Cl)=O)(C#N)CCCCl SKPGDHHYCYKJIK-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- WZNQLNOSNCIDDT-UHFFFAOYSA-N Cl.COC=1C=C(C(=O)NCC2(CCCN3CCC4=C(C23)NC2=CC=CC=C24)CC)C=C(C1OC)OC Chemical compound Cl.COC=1C=C(C(=O)NCC2(CCCN3CCC4=C(C23)NC2=CC=CC=C24)CC)C=C(C1OC)OC WZNQLNOSNCIDDT-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- BWSWPWLOTQQQJE-UHFFFAOYSA-N N-[(1-ethyl-3,4,6,7,12,12b-hexahydro-2H-indolo[2,3-a]quinolizin-1-yl)methyl]pentan-1-amine Chemical compound C(CCCC)NCC1(CCCN2CCC3=C(C12)NC1=CC=CC=C13)CC BWSWPWLOTQQQJE-UHFFFAOYSA-N 0.000 description 1
- QUVYJMCPSPPXBA-UHFFFAOYSA-N N-[(1-ethyl-3,4,6,7,12,12b-hexahydro-2H-indolo[2,3-a]quinolizin-1-yl)methyl]pentanamide Chemical compound C(CCCC)(=O)NCC1(CCCN2CCC3=C(C12)NC1=CC=CC=C13)CC QUVYJMCPSPPXBA-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- DMSZORWOGDLWGN-UHFFFAOYSA-N ctk1a3526 Chemical compound NP(N)(N)=O DMSZORWOGDLWGN-UHFFFAOYSA-N 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- YDVNLQGCLLPHAH-UHFFFAOYSA-N dichloromethane;hydrate Chemical compound O.ClCCl YDVNLQGCLLPHAH-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- BIOLXPNWHGJRAA-UHFFFAOYSA-N ethyl 2-carbonochloridoyl-5-chloro-2-ethylpentanoate Chemical compound CCOC(=O)C(CC)(C(Cl)=O)CCCCl BIOLXPNWHGJRAA-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- SIAPCJWMELPYOE-UHFFFAOYSA-N lithium hydride Chemical compound [LiH] SIAPCJWMELPYOE-UHFFFAOYSA-N 0.000 description 1
- 229910000103 lithium hydride Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 231100001224 moderate toxicity Toxicity 0.000 description 1
- UDGSVBYJWHOHNN-UHFFFAOYSA-N n',n'-diethylethane-1,2-diamine Chemical compound CCN(CC)CCN UDGSVBYJWHOHNN-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- XGISHOFUAFNYQF-UHFFFAOYSA-N pentanoyl chloride Chemical compound CCCCC(Cl)=O XGISHOFUAFNYQF-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB4920177 | 1977-11-25 | ||
PCT/FR1978/000043 WO1979000319A1 (fr) | 1977-11-25 | 1978-11-24 | Nouvelles indolo (2, 3-a) quinolizidines, leur preparation et leur utilisation therapeutique |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS54500053A JPS54500053A (zh) | 1979-11-08 |
JPS6147838B2 true JPS6147838B2 (zh) | 1986-10-21 |
Family
ID=10451538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54500118A Expired JPS6147838B2 (zh) | 1977-11-25 | 1978-11-24 |
Country Status (28)
Country | Link |
---|---|
JP (1) | JPS6147838B2 (zh) |
AR (1) | AR218514A1 (zh) |
AT (1) | AT372384B (zh) |
AU (1) | AU529108B2 (zh) |
BE (1) | BE872134A (zh) |
CA (1) | CA1100959A (zh) |
CH (1) | CH641181A5 (zh) |
DE (1) | DE2851028A1 (zh) |
DK (1) | DK154430C (zh) |
EG (1) | EG13683A (zh) |
ES (1) | ES475328A1 (zh) |
FI (1) | FI64372C (zh) |
FR (2) | FR2409755A1 (zh) |
HK (1) | HK60884A (zh) |
IE (1) | IE47518B1 (zh) |
IN (1) | IN151146B (zh) |
IT (1) | IT1160263B (zh) |
LU (1) | LU80576A1 (zh) |
MX (1) | MX5529E (zh) |
MY (1) | MY8500029A (zh) |
NL (1) | NL7811562A (zh) |
NO (1) | NO151288C (zh) |
NZ (1) | NZ188974A (zh) |
PT (1) | PT68825A (zh) |
SE (2) | SE431650B (zh) |
SG (1) | SG61182G (zh) |
WO (1) | WO1979000319A1 (zh) |
ZA (1) | ZA786426B (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3175900D1 (en) * | 1981-11-18 | 1987-03-12 | Thal Claude | Indoloquinolizine derivatives, process for their preparation and their therapeutic use |
FR2529552B1 (fr) * | 1982-07-05 | 1985-09-27 | Centre Nat Rech Scient | Nouveau procede de preparation d'intermediaires de synthese de la vindoline et intermediaires de synthese |
HU191454B (en) * | 1984-10-05 | 1987-02-27 | Richter Gedeon Vegyeszeti Gyar Rt.,Hu | Process for producing amides of oktahydro-indolo/2,3-a/quinolyzin-1-yl-alkanecarboxylic acids and pharmaceutically acceptable acid additional salts thereof |
HU194220B (en) * | 1985-04-19 | 1988-01-28 | Richter Gedeon Vegyeszet | Process for production of derivatives of 1,12 b disubstituated-octahydro-indolo /2,3-a/ quinolisine and medical compounds containing thereof |
HU195214B (en) * | 1985-04-19 | 1988-04-28 | Richter Gedeon Vegyeszet | Process for producing 12b-substituted-1-(hydroxymethyl)-octahydro-indolo /2,3-a/ quinolizine derivatives and pharmaceutical preparations comprising these compounds |
FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
ES2158896T3 (es) * | 1993-06-18 | 2001-09-16 | Fujisawa Pharmaceutical Co | Nuevo compuesto intermedio para uso en sintesis y procedimiento para producir un derivado de aminopiperazina. |
FR2713644B1 (fr) * | 1993-12-14 | 1996-02-09 | Adir | Nouveaux analogues de l'éburnane, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
FR2713643B1 (fr) * | 1993-12-14 | 1996-06-07 | Adir | Nouveaux analogues de l'éburnane, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
PT1532391E (pt) † | 2002-06-24 | 2009-06-25 | Saint Gobain Isover | Painel de isolamento para conduta de distribuição |
FR2911143A1 (fr) * | 2007-01-05 | 2008-07-11 | Servier Lab | Utilisation de composes neuroprotecteurs pour l'obtention de medicaments destines au traitement de maladies neurodegeneratives. |
FR2911141B1 (fr) * | 2007-01-05 | 2009-02-20 | Servier Lab | Nouveaux derives triazabenzo[a]naphtho[2,1,8-cde]azulene, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
FR2911142A1 (fr) * | 2007-01-05 | 2008-07-11 | Servier Lab | Nouveaux derives aminopyrrolo[1,2-a]indole et aminopyridazino[1,6-a]indole,leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU167366B (zh) * | 1972-09-06 | 1975-09-27 | ||
BE802387A (fr) * | 1973-07-16 | 1973-11-16 | Omnium Chimique Sa | Procede de preparation de la vincamone et de l'epi-21 vincamone a partir de la tabersonine et derives indoliques nouveaux. |
HU169916B (zh) * | 1974-09-27 | 1977-02-28 | ||
HU171165B (hu) * | 1974-11-26 | 1977-11-28 | Richter Gedeon Vegyeszet | Sposob poluchenija proizvodnykh oktagidro-indolo-skobka-2,3-a-skobka zakryta-kinolizina |
FR2315277A1 (fr) * | 1975-06-25 | 1977-01-21 | Anvar | Nouveaux derives pentacycliques, leur preparation et les compositions qui les contiennent |
-
1978
- 1978-11-15 ZA ZA00786426A patent/ZA786426B/xx unknown
- 1978-11-20 BE BE191824A patent/BE872134A/xx not_active IP Right Cessation
- 1978-11-22 NZ NZ188974A patent/NZ188974A/xx unknown
- 1978-11-23 FI FI783581A patent/FI64372C/fi not_active IP Right Cessation
- 1978-11-23 AT AT0837478A patent/AT372384B/de active
- 1978-11-23 AR AR274552A patent/AR218514A1/es active
- 1978-11-23 ES ES475328A patent/ES475328A1/es not_active Expired
- 1978-11-23 AU AU41874/78A patent/AU529108B2/en not_active Expired
- 1978-11-23 NO NO783958A patent/NO151288C/no unknown
- 1978-11-23 PT PT68825A patent/PT68825A/pt unknown
- 1978-11-24 DE DE19782851028 patent/DE2851028A1/de active Granted
- 1978-11-24 IE IE2328/78A patent/IE47518B1/en unknown
- 1978-11-24 LU LU80576A patent/LU80576A1/xx unknown
- 1978-11-24 WO PCT/FR1978/000043 patent/WO1979000319A1/fr unknown
- 1978-11-24 MX MX787557U patent/MX5529E/es unknown
- 1978-11-24 JP JP54500118A patent/JPS6147838B2/ja not_active Expired
- 1978-11-24 FR FR7833176A patent/FR2409755A1/fr active Granted
- 1978-11-24 IN IN851/DEL/78A patent/IN151146B/en unknown
- 1978-11-24 CH CH683579A patent/CH641181A5/fr not_active IP Right Cessation
- 1978-11-24 DK DK524978A patent/DK154430C/da not_active IP Right Cessation
- 1978-11-24 FR FR7833175A patent/FR2423492A1/fr active Granted
- 1978-11-24 NL NL7811562A patent/NL7811562A/xx not_active Application Discontinuation
- 1978-11-24 CA CA316,809A patent/CA1100959A/en not_active Expired
- 1978-11-24 IT IT30171/78A patent/IT1160263B/it active
- 1978-11-25 EG EG669/78A patent/EG13683A/xx active
-
1979
- 1979-07-23 SE SE7906287A patent/SE431650B/sv not_active IP Right Cessation
-
1980
- 1980-11-07 SE SE8007845A patent/SE435622B/sv not_active IP Right Cessation
-
1982
- 1982-12-03 SG SG611/82A patent/SG61182G/en unknown
-
1984
- 1984-08-02 HK HK608/84A patent/HK60884A/xx unknown
-
1985
- 1985-12-30 MY MY29/85A patent/MY8500029A/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SK32000A3 (en) | Method for the preparation of citalopram, a pharmaceutical composition containing the same and intermediates | |
JPS626703B2 (zh) | ||
CZ292077B6 (cs) | Způsob výroby soli citalopramu | |
FR2735127A1 (fr) | Nouvelles piperazines heteroaromatiques utiles comme medicaments. | |
JPS6147838B2 (zh) | ||
JPS60358B2 (ja) | ベンゾモルフアン化合物の製法 | |
FR2630328A1 (fr) | Derive de l'histamine, sa preparation et son application en therapeutique | |
JP2004534063A (ja) | ミコフェノール酸モフェチルの調製法 | |
JPS59152366A (ja) | 新規ニトロ脂肪族化合物、その製造法およびその用途 | |
JPH0615527B2 (ja) | アルキルジアミン誘導体、その製造法および抗不整脈剤 | |
JPH08319274A (ja) | 4−インドリルピペラジニル誘導体 | |
JPH04279565A (ja) | 4−クロロ−3−スルファモイル−n−(2,3−ジヒドロ−2−メチル−1h−インドール−1−イル)ベンズアミドの新規な工業的製造方法 | |
EP0021857A1 (fr) | Dérivés de l'indole, leur préparation et medicaments les contenant | |
DE3719699A1 (de) | Indolderivate | |
US4353911A (en) | Indolo(2,3-a)quinolizidines, useful in increasing femoral and vertebral blood flow | |
JP2909145B2 (ja) | β―ラクタマーゼ抑止剤の製法 | |
US4831167A (en) | Process for diastereoselective reduction of 3-amino-1-benzoxepin-5(2H)-ones | |
JPH04308557A (ja) | アルキルアミノアルキルアミン−および−エーテル化合物、その製造方法、およびそれを含有する胃腸管の鎮痙用の医薬 | |
JPH0430389B2 (zh) | ||
WO1998042710A1 (fr) | Derives de dihydropyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique | |
KR100503518B1 (ko) | 2-(4-알킬-1-피페라지닐)-벤즈알데하이드 및 -벤질리데닐화합물의 제조 방법 | |
JPH05201978A (ja) | N−(4,7−ジメトキシ−2−インダニル)−1−(フェニルカルボニル)−n−プロピル−4−ピペリジンメタンアミン誘導体、その製造法および医薬への応用 | |
US4141988A (en) | 2,9-Dioxatricyclo[4,3,1,03,7 ]decane derivatives, processes for their preparation and pharmaceutical compositions thereof | |
CH620678A5 (en) | Process for the preparation of a derivative of piperidine | |
KR820000497B1 (ko) | 신규한 인돌로(2, 3-a)퀴놀리지딘류의 제조방법 |